Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Molecular Pathways and Mechanisms of LAG-3 in Cancer Therapy

Lawrence P. Andrews, Anthony R. Cillo, Lilit Karapetyan, John M. Kirkwood, Creg J. Workman, Dario A.A. Vignali

Clin Cancer Res OF1–OF10.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-2390

Published: 26 May 2022

View article

Journal Articles

Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

Clin Cancer Res (2021) 27 (15): 4195–4204.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4301

Published: 01 August 2021

View article

Includes: Supplementary data

Journal Articles

The State of Melanoma: Emergent Challenges and Opportunities

Clin Cancer Res (2021) 27 (10): 2678–2697.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4092

Published: 15 May 2021

View article

Journal Articles

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

Joe-Marc Chauvin, Mignane Ka, Ornella Pagliano, Carmine Menna, Quanquan Ding, Richelle DeBlasio, Cindy Sanders, Jiajie Hou, Xian-Yang Li, Soldano Ferrone, Diwakar Davar, John M. Kirkwood, Robert J. Johnston, Alan J. Korman, Mark J. Smyth, Hassane M. Zarour

Clin Cancer Res (2020) 26 (20): 5520–5533.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-0575

Published: 15 October 2020

View article

Includes: Supplementary data

Journal Articles

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

Clin Cancer Res (2020) 26 (7): 1725–1735.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-3717

Published: 01 April 2020

View article

Includes: Supplementary data

Journal Articles

E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma

Ahmad A. Tarhini, Sandra J. Lee, Xiaoxue Li, Uma N.M. Rao, Arun Nagarajan, Mark R. Albertini, Jerry W. Mitchell, Jr, Stuart J. Wong, Mark A. Taylor, Noel Laudi, Phu V. Truong, Robert M. Conry, John M. Kirkwood

Clin Cancer Res (2019) 25 (2): 524–532.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-2258

Published: 15 January 2019

View article

Includes: Supplementary data

Journal Articles

Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690

Mohammed Kashani-Sabet, Mehdi Nosrati, James R. Miller, III, Richard W. Sagebiel, Stanley P.L. Leong, Andrew Lesniak, Schuyler Tong, Sandra J. Lee, John M. Kirkwood

Clin Cancer Res (2017) 23 (22): 6888–6892.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-1317

Published: 14 November 2017

View article

Journal Articles

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

Lisa H. Butterfield, Fengmin Zhao, Sandra Lee, Ahmad A. Tarhini, Kim A. Margolin, Richard L. White, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, John M. Kirkwood, David H. Lawson

Clin Cancer Res (2017) 23 (17): 5034–5043.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-3016

Published: 31 August 2017

View article

Includes: Supplementary data

Journal Articles

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma

Melissa A. Wilson, Fengmin Zhao, Sanika Khare, Jason Roszik, Scott E. Woodman, Kurt D'Andrea, Bradley Wubbenhorst, David L. Rimm, John M. Kirkwood, Harriet M. Kluger, Lynn M. Schuchter, Sandra J. Lee, Keith T. Flaherty, Katherine L. Nathanson

Clin Cancer Res (2016) 22 (2): 374–382.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-1162

Published: 14 January 2016

View article

Includes: Supplementary data

Journal Articles

CCR 20^th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma—Kinase Inhibition Redux

Diwakar Davar, John M. Kirkwood

Clin Cancer Res (2015) 21 (24): 5412–5414.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-3132

Published: 14 December 2015

View article

Journal Articles

Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib

Melissa A. Wilson, Fengmin Zhao, Richard Letrero, Kurt D'Andrea, David L. Rimm, John M. Kirkwood, Harriet M. Kluger, Sandra J. Lee, Lynn M. Schuchter, Keith T. Flaherty, Katherine L. Nathanson

Clin Cancer Res (2014) 20 (12): 3328–3337.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-0093

Published: 12 June 2014

View article

Includes: Supplementary data

Journal Articles

ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)

Ronald S. Go, Sandra J. Lee, Donghoon Shin, Steven M. Callister, Dean A. Jobe, Robert M. Conry, Ahmad A. Tarhini, John M. Kirkwood

Clin Cancer Res (2013) 19 (23): 6597–6604.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-1414

Published: 01 December 2013

View article

Includes: Supplementary data

Journal Articles

A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)

Craig L. Slingluff, Jr, Sandra Lee, Fengmin Zhao, Kimberly A. Chianese-Bullock, Walter C. Olson, Lisa H. Butterfield, Theresa L. Whiteside, Philip D. Leming, John M. Kirkwood

Clin Cancer Res (2013) 19 (15): 4228–4238.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-0002

Published: 31 July 2013

View article

Includes: Supplementary data

Journal Articles

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

Kim A. Margolin, James Moon, Lawrence E. Flaherty, Christopher D. Lao, Wallace L. Akerley, III, Megan Othus, Jeffrey A. Sosman, John M. Kirkwood, Vernon K. Sondak

Clin Cancer Res (2012) 18 (4): 1129–1137.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-2488

Published: 14 February 2012

View article

Journal Articles

New Challenges in Endpoints for Drug Development in Advanced Melanoma

Antoni Ribas, Peter Hersey, Mark R. Middleton, Helen Gogas, Keith T. Flaherty, Vernon K. Sondak, John M. Kirkwood

Clin Cancer Res (2012) 18 (2): 336–341.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-2323

Published: 16 January 2012

View article

Journal Articles

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazulina, Karin Kemsley, Reinhard Dummer

Clin Cancer Res (2012) 18 (2): 555–567.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-1491

Published: 16 January 2012

View article

Includes: Supplementary data

Journal Articles

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

Kevin B. Kim, Jason Chesney, Douglas Robinson, Humphrey Gardner, Michael M. Shi, John M. Kirkwood

Clin Cancer Res (2011) 17 (23): 7451–7461.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-1747

Published: 30 November 2011

View article

Includes: Supplementary data

Journal Articles

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

Ahmad A. Tarhini, Paul Frankel, Kim A. Margolin, Scott Christensen, Christopher Ruel, Janice Shipe-Spotloe, David R. Gandara, Alice Chen, John M. Kirkwood

Clin Cancer Res (2011) 17 (20): 6574–6581.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-1463

Published: 14 October 2011

View article

Includes: Supplementary data

Journal Articles

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

John M. Kirkwood, Paul Lorigan, Peter Hersey, Axel Hauschild, Caroline Robert, David McDermott, Margaret A. Marshall, Jesus Gomez-Navarro, Jane Q. Liang, Cecile A. Bulanhagui

Clin Cancer Res (2010) 16 (3): 1042–1048.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-2033

Published: 01 February 2010

View article

Journal Articles

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8⁺ and CD4⁺ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

Craig L. Slingluff, Jr., Gina R. Petroni, Walter C. Olson, Mark E. Smolkin, Merrick I. Ross, Naomi B. Haas, William W. Grosh, Marc E. Boisvert, John M. Kirkwood, Kimberly A. Chianese-Bullock

Clin Cancer Res (2009) 15 (22): 7036–7044.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-1544

Published: 11 November 2009

View article

Includes: Supplementary data

NARROW

Molecular Pathways and Mechanisms of LAG-3 in Cancer Therapy

Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

The State of Melanoma: Emergent Challenges and Opportunities

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma

Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma

CCR 20^th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma—Kinase Inhibition Redux

Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib

ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)

A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

New Challenges in Endpoints for Drug Development in Advanced Melanoma

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8⁺ and CD4⁺ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only